Drug target (Synonym) | Compound (Synonym) | Status | Indication | ClinicalTrials.gov identifier |
---|---|---|---|---|
CD134 (OX40) CD137 (ILA, 4-IBB) | PF-04518600 Utomilumab (PF-05082566) | Phase I | Neoplasms | NCT02315066 |
CD134 (OX40) CD137 (ILA, 4-IBB) CD274 (PDL1) | PF-04518600 Utomilumab (PF-05082566) Avelumab (MSB-0010718C) | Phase I | Neoplasms | NCT02554812 |
CD137 (ILA, 4-IBB) CD279 (PD1) | PF-05082566 MK-3475 | Phase I | Advanced solid tumors | NCT02179918 |
CD123 (OX40) CD274 (PDL1) VEGF | MOXR0916 Atezolizumab (MPDL-3280A) Bevacizumab | Phase I | Advanced or metastatic solid tumors | NCT02410512 |
CD134 (OX40) CD152 (CTLA4) CD274 (PDL1) | MEDI-0562 Tremelimumab (CP-675,206) Durvalumab (MEDI-4736) | Phase I | Advanced or metastatic solid tumors | NCT02705482 |
CD134 (OX40) CD152 (CTLA4) CD274 (PDL1) | MEDI-6469 Tremelimumab (CP-675,206) Durvalumab (MEDI-4736) | Phase I/II | Advanced solid tumors or DLBCL | NCT02205333 |
CD252 (OX40L) CD274 (PDL1) | MEDI-6383 Durvalumab (MEDI-4736) | Phase I | Recurrent or metastatic solid tumors | NCT02221960 |
CD276 (B7-H3) CD152 (CTLA4) | Enoblituzumab (MGA-271) Ipilimumab | Phase I | B7-H3 expressing solid tumors | NCT02381314 |
CD276 (B7-H3) CD279 (PD1) | Enoblituzumab (MGA-271) Pembrolizumab | Phase I | B7-H3 expressing solid tumors | NCT02475213 |
VISTA CD274 (PDL1) | CA-170 (AUPM-170) | Phase I | Advanced solid tumors or lymphomas, non-responsive to available therapies | NCT02812875 |
CD152 (CTLA4) CD274 (PDL1) Cytotoxic | Tremelimumab (CP-675,206) Durvalumab (MEDI-4736) Chemotherapy | Phase I Phase I Phase I | Resectable CRC with liver metastases Solid malignancies Multiple Myeloma | NCT02754856 NCT02537418 NCT02716805 |
CD152 (CTLA4) CD274 (PDL1) Cytotoxic | Tremelimumab (CP-675,206) Durvalumab (MEDI-4736) Radiotherapy | Phase I Phase II Phase II | Unresectable pancreatic cancer NSCLC, CRC Relapsed SCLC | NCT02311361 NCT02888743 NCT02701400 |
CD152 (CTLA4) CD274 (PDL1) | Tremelimumab (CP-675,206) Durvalumab (MEDI-4736) | Phase I Phase II Phase II Phase II Phase III | Advanced solid tumors Unresectable hepatocellular carcinoma Metastatic Her2 negative breast cancer Head and neck cancer NSCLC | NCT02261220 NCT02519348 NCT02536794 NCT02319044 NCT02453282 |
CD274 (PDL1) CD279 (PD1) | Durvalumab (MEDI-4736) MEDI-0680 | Phase I/II | Advanced malignancies | NCT02118337 |
CD137 (ILA, 4-IBB) CD279 (PD1) | Urelumab Nivolumab (BMS-936558) | Phase I Phase II | Recurrent glioblastoma Cisplatin-ineligible bladder carcinoma | NCT02658981 NCT02845323 |
CD152 (CTLA4) CD137 (ILA, 4-IBB) | Ipilimumab BMS-663513 | Phase I | Advanced melanoma | NCT00803374 |
CD223 (LAG3) CD279 (PD1) | BMS-986016 Nivolumab (BMS-936558) | Phase I | Relapsed hematologic malignancies | NCT02061761 |
CD366 (TIM3) CD279 (PD1) | MBG-453 PDR-001 | Phase I/II | Advanced malignancies | NCT02608268 |
CD279 (PD1) CD357 (GITR) | PDR-001 GWN-323 | Phase I/II | Advanced malignancies and lymphomas | NCT02740270 |
CD279 (PD1) CD223 (LAG3) | PDR-001 LAG-525 | Phase I/II | Advanced malignancies | NCT02460224 |
CD357 (GITR) CD279 (PD1) | MK-4166 Pembrolizumab (MK-3475) | Phase I | Advanced solid tumors | NCT02132754 |